000			01206nam a22001577a 4500
999			_c517613 _d517613
008			210722b ||||| |||| 00| 0 eng d
100			_aDranove, David, Ody, Christopher and Starc, Amanda _927339
245			_aA dose of managed care: Controlling drug spending in Medicaid
260			_aAmerican Economic Journal: Applied Economics
300			_a13(1), Jan, 2021: p.170-197
520			_aWe study the effect of privatizing Medicaid drug benefits on drug prices and utilization. Drug spending would decrease by 21.3 percent if private insurers administered all drug benefits. One-third of the decrease is driven by private insurers' ability to negotiate prices with pharmacies. The remaining two-thirds is driven by the greater use of lower cost drugs, such as generics, and is only realized in states that give private insurers the flexibility to design drug benefits. Privatization does not reduce prescriptions per enrollee and spending cuts are smaller for drugs that lower medical spending. – Reproduced
650			_aGovernment policy - Health, Health regulation, Public health _927340
773			_aAmerican Economic Journal: Applied Economics
906			_aHEALTH SERVICES
942			_cAR